BioCryst is profitable. Now it wants to buy more rare disease drugs
Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.
Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers. This story matters for Finance & Markets readers tracking fund. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. FundNews curates and briefs the finance & markets stories that matter. Our editorial policy →